chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride - Profile

What are the generic drug sources for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride and what is the scope of freedom to operate?

Chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride has thirty-four patent family members in eighteen countries.

Summary for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride

International Patents:	34
US Patents:	1
Tradenames:	2
Applicants:	1
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	CHILDREN'S ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	SUSPENSION;ORAL	021587-001	Feb 24, 2004		OTC	Yes	Yes
Haleon Us Holdings	ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	TABLET;ORAL	021441-001	Dec 19, 2002		OTC	Yes	Yes			Y

Expired US Patents for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	CHILDREN'S ADVIL ALLERGY SINUS	chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride	SUSPENSION;ORAL	021587-001	Feb 24, 2004

International Patents for chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Argentina	042543	COMPOSICIONES DE ANTI-HISTAMINICOS, DESCONGESTIVOS Y DROGAS ANTI-INFLAMATORIAS NO ESTEROIDES
Australia	2003301188	COMPOSITIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND ANTI-HISTAMINES
Australia	2005251733	Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines
Australia	2011200912	Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
Canada	2508611	COMPOSITIONS DE MEDICAMENTS ANTI-INFLAMMATOIRES NON-STEROIDAUX, DECONGESTIONNANTS ET ANTIHISTAMINIQUES (COMPOSITIONS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DECONGESTANTS AND ANTI-HISTAMINES)
Canada	2568443	COMPRIME MULTICOUCHE COMPRENANT DES MEDICAMENTS ANTI-INFLAMMATOIRES NON STEROIDIENS, DES DECONGESTIONNANTS ET DES ANTIHISTAMINIQUES NON SEDATIFS (MULTI-LAYER TABLET COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, DECONGESTANTS AND NON-SEDATING ANTIHISTAMINES)

Investment Scenario, Market Dynamics, and Financial Trajectory for Chlorpheniramine Maleate, Ibuprofen, and Pseudoephedrine Hydrochloride

Last updated: February 3, 2026

Summary

This report evaluates the current market landscape, investment prospects, and financial trajectories of three key pharmaceuticals: chlorpheniramine maleate, ibuprofen, and pseudoephedrine hydrochloride. It analyzes production volumes, regulatory environments, supply chain considerations, market demand, and pricing trends. The focus aims to aid investors, manufacturers, and industry strategists in understanding growth opportunities and risks associated with these medications.

---

Introduction

Drug Name	Therapeutic Class	Principal Use	Regulatory Status	Market Overview	Price Trends	Key Manufacturers
Chlorpheniramine Maleate	First-generation antihistamine	Allergic rhinitis, cold symptoms	Approved globally, OTC availability	Stable, but facing generic saturation	Price declining due to generic competition	Johnson & Johnson, Teva, Mylan
Ibuprofen	Nonsteroidal anti-inflammatory drug (NSAID)	Pain, inflammation, fever	OTC and prescription in some markets	Large and mature, steady growth	Moderate price decline; high-volume sales	BASF, Johnson & Johnson, Novartis
Pseudoephedrine Hydrochloride	Decongestant	Nasal congestion	Restricted OTC in many jurisdictions	Vulnerable to regulation, but consistent demand	Price influenced by regulatory bottlenecks	Glenmark, Apotex, Others

---

Market Dynamics Analysis

1. Market Size and Growth

Drug	Global Market Size (USD billion)	CAGR (2018-2023)	Forecast (2023-2028)	Key Drivers
Chlorpheniramine Maleate	$0.4	2%	$0.45	OTC demand, allergy prevalence
Ibuprofen	$6.5	4%	$8.0	Pain management, OTC popularity
Pseudoephedrine Hydrochloride	$1.2	3%	$1.4	Cold/flu seasonality, regulation shifts

Source: MarketResearch.com, 2023

2. Regulatory and Supply Chain Factors

• Chlorpheniramine Maleate: Widely approved globally; low regulatory hurdles; supply chain stable with multiple generic players.
• Ibuprofen: WTO/TRIPS compliant; regulated as OTC; supply chain complex due to raw material sourcing (pyrazolone derivatives).
• Pseudoephedrine Hydrochloride: Subject to stringent legal controls (e.g., Combat Methamphetamine Epidemic Act, USA); supply chain vulnerable to regulatory changes.

3. Pricing and Profitability Trends

Drug	Typical Wholesale Price (per pack)	Price Volatility	Patent Status	Market Competition
Chlorpheniramine	$0.10 - $0.15	Low	Expired patents	High (generic dominance)
Ibuprofen	$0.20 - $0.30	Moderate	Patents expired	Very high (over-the-counter)
Pseudoephedrine	$0.30 - $0.50	High	No patent	Moderate – sensitive to regulation

Note: Prices vary geographically; current data sourced from industry reports (2023).

---

Financial Trajectory and Investment Outlook

1. Revenue & Profitability Forecasts

Drug	Estimated 2023 Revenue (USD million)	EBITDA Margin	Growth Drivers	Risks
Chlorpheniramine	$82	15-20%	Stable OTC demand	Market saturation
Ibuprofen	$650	20-30%	High-volume sales	Price erosion, raw material costs
Pseudoephedrine	$120	10-15%	Consistent seasonal demand	Regulatory restrictions

2. Investment Opportunities & Risks

Opportunity	Rationale	Risks
Expand OTC formulations	High demand for allergy and pain medications	Market saturation, price pressure
R&D for novel antihistamines	Potential for premium positioning	Development costs, regulatory hurdles
Supply chain diversification for pseudoephedrine	Reducing regulatory reliance	Capital expenditure, political risks

---

Comparative Analysis

Aspect	Chlorpheniramine Maleate	Ibuprofen	Pseudoephedrine Hydrochloride
Market Size (USD bn)	0.4	6.5	1.2
CAGR (2018-2023)	2%	4%	3%
Patent Status	Expired	Expired	Expired but regulatory heavily restrictions
Price Trend	Declining	Stable-to-declining	Volatile, affected by regulation
Major Market Regions	North America, Europe, Asia	Global	US, Europe, select Asia
Major Application	Allergic rhinitis	Pain, fever	Nasal congestion

Note: The above reflects compiled industry data and projections.

---

Supply Chain and Regulatory Considerations

• Chlorpheniramine Maleate:

  • Supply chain resilient with multi-sourcing.
  • Limited regulatory risks due to OTC status.

• Ibuprofen:

  • Raw materials (pyrazolone derivatives) sourced largely from Asia.
  • Increasing focus on sustainable sourcing and quality.

• Pseudoephedrine Hydrochloride:

  • Heavily regulated.
  • Increasing usage of alternative manufacturing locations (e.g., India, China).

Impact of Regulations on Market Dynamics

Regulation	Impact on Pseudoephedrine	Impact on Other Drugs
US Combat Methamphetamine Act	Significant reduction in supply	No direct impact
EU medicinal regulation	Moderate	Stable
India’s Drug Laws	Increasing oversight	Growing participation

---

Future Market Trajectory

Forecast Metrics	2023	2028 (Projected)
Market volume (units)	15 billion units	20 billion units
Revenue growth	4% annually	5% annually
Formulation trends	More combination OTCs	Shift toward natural and targeted medications

Conclusion

• Chlorpheniramine maleate remains a stable, low-risk OTC antihistamine with moderate growth prospects, primarily driven by allergy prevalence.
• Ibuprofen dominates the NSAID market with high volume and steady demand, with potential risks from price erosion and raw material costs.
• Pseudoephedrine hydrochloride offers consistent seasonal demand but faces regulatory and compliance challenges, constraining immediate scalability.

Investors should consider market maturity, regulatory environments, raw material sourcing, and technological innovation in strategic planning. Diversification across formulation types and geographic regions mitigates risks and enhances growth potential.

---

Key Takeaways

• OTC drugs like chlorpheniramine maleate and ibuprofen offer significant but mature market opportunities; competition primarily drives margins downward.
• Pseudoephedrine's regulatory environment is a key determinant of its market stability; alternative manufacturing hubs mitigate risks.
• Long-term growth hinges on innovation in formulations, regulatory adaptation, and supply chain diversification.
• Industry participants should monitor raw material prices, regulatory updates, and consumer trends in allergy, pain, and cold remedies.

---

FAQs

1. How will regulatory restrictions on pseudoephedrine impact future investments?
Increased regulation constrains supply and can elevate production costs. Alternative manufacturing sources and substitution with non-restricted compounds are strategic responses; however, investment risks remain due to potential legislative changes.

2. What are the main competitive advantages for ibuprofen manufacturers?
High global demand, well-established OTC classification, and diverse formulations provide scalability. Cost-effective raw material sourcing and robust distribution channels are critical.

3. Are there emerging therapies replacing chlorpheniramine maleate?
Yes, second-generation antihistamines like loratadine and cetirizine offer fewer side effects, gaining market share. Nonetheless, chlorpheniramine remains relevant due to low cost and OTC availability.

4. What is the impact of raw material costs on these drugs’ profitability?
Fluctuations in raw material prices, especially for ibuprofen's precursor chemicals, influence margins. Supply chain stability and raw material diversification are essential for maintaining profit margins.

5. Which markets present the highest growth potential?
Asia-Pacific, due to increasing healthcare access and allergy prevalence; and emerging markets in Latin America and Africa, where OTC medication penetration is expanding.

---

References

[1] MarketResearch.com, “Global Over-the-Counter (OTC) Drugs Market,” 2023.
[2] IQVIA Institute, “The Impact of Regulation on Pseudoephedrine Supply,” 2022.
[3] GlobalData, “Pharmaceutical Industry Outlook,” 2023.
[4] US FDA, “Guidelines and Regulations for OTC Drugs,” 2022.
[5] Pharma Intelligence, “Raw Material Pricing Trends in the Pharmaceutical Industry,” 2023.

---